About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Biotech Specialist and Glaxo Finalize a $350 Cancer Deal

by Himabindu Venkatakrishnan on June 3, 2014 at 1:22 PM
Font : A-A+

 Biotech Specialist and Glaxo Finalize a $350 Cancer Deal

A $350-million deal has been finalized between British pharmaceuticals giant GlaxoSmithKline and Adaptimmune to help develop and sell the biotechnology firm's cancer drugs, the companies said on Monday.

Adaptimmune announced in a statement that it has entered a "strategic cancer immunotherapy collaboration" with GSK to "develop and commercialise novel cell-based therapies" in its lead clinical cancer programme.

Advertisement

The biotech firm, which is based in Oxford, southern England and Philadelphia, has had success in trials in using T-cells, the heavy weaponry of the immune system, to target cancer cells.

The GSK deal, worth the equivalent of 260 million euros could yield payments in excess of $350 million to Adaptimmune over the next seven years, according to the statement.
Advertisement

There would also be "significant" additional development and commercialisation payments in subsequent years, if GSK exercises all its options and milestones continue to be met.

Adaptimmune would also receive royalties ranging from single to double digits on net sales.

The statement added that trials in Adaptimmune's lead programme, in multiple myeloma, melanoma, sarcoma and ovarian cancer in the United States, are generating "encouraging" results. European trials are set to start shortly.

Monday's announcement meanwhile follows the collapse last week of US drugs giant Pfizer's $117-billion takeover offer for GSK's key British rival AstraZeneca.

It also comes after GSK agreed last month to sell its oncology business to peer Novartis for $16 billion and to buy the Swiss group's vaccines division.

Source: AFP
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Cancer News

Cancer Drugs to be Tested in Orbit During American Private Astronaut Mission
The mission of Axiom Space incorporated numerous experiments focusing on human stem cell aging, inflammation, and cancer within the laboratory situated in the low Earth orbit.
 Hydrogen Sulfide Makes Cancer Cells More Sensitive to Photothermal Therapy
Providing a sustained supply of hydrogen sulfide to cancer cells, could be a remodeling strategy to improve photothermal therapy efficacy while minimizing side effects.
Hidden Influence of Gut Microbiome on Early-Onset Colorectal Cancer
Colon cancer's hidden link revealed in microbiome study.
Telephone-based Weight Loss Program Helps Breast Cancer Patients Shed Pounds
Breast cancer patients in the obese or overweight category can greatly benefit from a telephone-based weight management program in achieving significant weight loss.
 Tobacco Use Among Cancer Patients Likely to Increase Symptom Burden
A new study assessed the association of cigarette smoking and vaping on cancer-related symptom burden (fatigue, pain, emotional problems) and quality of life.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Biotech Specialist and Glaxo Finalize a $350 Cancer Deal Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests